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Abstract
Background: Based on the prodrug principle, aspirin and eugenol, as starting precursors, were esterified to
synthesize aspirin eugenol ester (AEE). The aim of the present study was to evaluate the antithrombotic effect of
AEE in an animal disease model. In order to compare the therapeutic effects of AEE and its precursors, aspirin,
eugenol and a combination of aspirin and eugenol were designed at the same molar quantities as the AEE
medium dose in the control group.
Methods: After oral administration of AEE (dosed at 18, 36 and 72 mg/kg) for seven days, rats were treated with
k-carrageenan to induce tail thrombosis. Following the same method, aspirin (20 mg/kg), eugenol (18 mg/kg) and
0.5 % CMC-Na (30 mg/kg) were administered as control drug. Different drug effects on platelet aggregation,
hemorheology, TXB2/6-keto-PGF1α ratio and blood biochemistry were studied.
Results: AEE significantly inhibited ADP and AA-induced platelet aggregation in vivo. AEE also significantly reduced
blood and plasma viscosity. Moreover, AEE down-regulated TXB2 and up-regulated 6-keto-PGF1α, normalizing the
TXB2/6-keto-PGF1α ratio and blood biochemical profile. In comparison with aspirin and eugenol, AEE produced
more positive therapeutic effects than its precursors under the same molar quantity.
Conclusion: It may be concluded that AEE was a good candidate for new antithrombotic and antiplatelet
medicine. Additionally, this study may help to understand how AEE works on antithrombosis in different ways.
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Background
In the last century, remarkable increases of life spans in
dogs and cats have promoted the development of geriatric
veterinary medicine [1, 2]. The findings have proved that
age-related thrombin was a possible risk factor in dogs
and cats [3, 4]. Thus, there is a need for anti-thrombotic
drugs for animals. The physiological process of throm-
bosis is complex and influenced by many factors such as
platelet aggregation, ratio of thromboxane B2 (TXB2) to 6-
keto prostaglandin F1α (6-keto-PGF1α), biochemical and
hemorheological parameters [5–8]. Therefore, the impacts
of drugs on platelet aggregation, hemorheology, TXB2/6-
keto-PGF1α ratio and blood biochemistry can be employed
for examining the effect of compound in thrombosis
prevention [9].
Aspirin is extensively used in human and veterinary
medicine to reduce inflammation, pain and fever. In cats,
aspirin is not well tolerated because of the deficient in
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glucuronate and has a prolonged elimination half-time. The
pharmacodynamics of aspirin are similar in human and
dogs. Related researches have proved that prophylactic use
of aspirin can reduce the risk of heart attack, stroke and
some cancers [10, 11]. A number of reports have showed
that eugenol has antiseptic, analgesic, antibacterial, anti-
platelet aggregation and anticancer properties [12–14]. Not-
ably, aspirin and eugenol produce similar pharmacological
effects especially on inflammation and platelet aggregation.
Gastrointestinal damage caused by aspirin and vulner-
ability of eugenol limit their application. These side effects
and structural instability are related to chemically carboxyl
group of aspirin and hydroxyl group of eugenol. In order
to increase therapeutic effect and stabilization, aspirin and
eugenol as starting precursors were esterified to synthesize
aspirin eugenol ester (AEE). AEE, a pale yellow, odorless
crystal, overcomes the disadvantages of its precursors.
Anti-ulcerogenic activity of eugenol has been confirmed
in a previous study, in which eugenol (100 mg/kg, p.o.)
significantly and dose-dependently reduced gastric ulcers
induced by platelet activating factor and ethanol in Wistar
rats [15]. So a combination of eugenol and aspirin could
play complementary roles to reduce gastrointestinal dam-
age and enhance the therapeutic effects. A 15-day sub-
chronic toxicity study identified that no histopathological
changes was observed in any organ from the rats following
low-dose AEE (50 mg/kg), whereas mucosa height of
stomach, duodenum and ileum were increased in rats
following high-dose AEE exposure (2000 mg/kg) [16].
Carrageenan-induced rat tail thrombosis model has
been widely used to evaluate whether substances have
antithrombotic effects during the drug discovery stage
[17–20]. The length of thrombosis in rat tail directly re-
flects the effects of drug on thrombosis formation [21, 22].
The preventive effects of AEE on thrombosis formation
have been confirmed in k-carrageenan-induced rat tail
thrombosis model, in which AEE significantly inhibited
thrombus formation and reduced the tail thrombosis
length [23]. However, investigations of the preventive ef-
fects of AEE against thrombosis are not sufficient. In
order to understand and illustrate the possible underlying
mechanism of AEE, a follow-up study was carried out
using the same animal disease model and drug dosage.
The aim of the present study was to evaluate the effects of
AEE on platelet aggregation, hemorheology, blood bio-
chemistry and TXB2/6-keto-PGF1α ratio. To compare the
effects of AEE and its precursors, equimolar doses of as-
pirin, eugenol and combination of aspirin and eugenol
were also administered in the experiment.
Methods
Chemicals and reagents
AEE (transparent crystal, 99.5 % purity with RP-HPLC)
was prepared in Key Lab of New Animal Drug Project of
Gansu Province, Key Lab of Veterinary Pharmaceutical
Development of Agricultural Ministry, Lanzhou Institute
of Husbandry and Pharmaceutical Sciences of CAAS.
CMC-Na was supplied by Tianjin Chemical Reagent
Company (Tianjin, China). Aspirin and Tween-80 were
obtained from Aladdin Industrial Corporation (Shanghai
China). Eugenol was supplied by Sinopharm Chemical
Reagent Co., Ltd. (Shanghai China). Adenosine diphos-
phate (ADP), arachidonic acid (AA) and k-carrageenan
were purchased from Sigma (St. Louis, USA). Blood
biochemical analysis reagents were obtained from
Meikang Co., Ltd (Zhejiang, China). All chemical re-
agents were of analytical reagent grade. A Thermo
Fisher Scientific Multiskan Go 1510 was used for spec-
trophotometry (USA).
Animals and treatment
Ninety male Wistar rats (approximately 160 g) were pur-
chased from the animal breeding facilities of Lanzhou
Army General Hospital (Lanzhou, China). Animals were
housed in plastic cages (size: 50 × 35 × 20 cm, 10 rats
per cage) with stainless steel wire cover and chopped
bedding in a ventilated room. The light/dark regime
was 12/12 h and living temperature was maintained
at 22 ± 2 °C with relative humidity of 55 ± 10 %. The
animals had free access to a standard diet and tap
water (Standard compressed rat feed from Keao Xieli
Co., Ltd., Beijing, China). Rats were allowed a 2-week
acclimation period prior to the start of experiment.
Drug preparation
AEE and aspirin suspensions were prepared in 0.5 % of
CMC-Na. Eugenol and Tween-80 (mass ratio of 1:2)
were mixed with distilled water. Kappa-carrageenan
(k-carrageenan) was dissolved in physiological saline.
Study design
Ninety rats were divided into 9 groups in the study. Ac-
cording to individual body weight (BW), rats were intra-
gastrically (i.g.) administered with 18, 36 and 72 mg/kg
AEE, 20 mg/kg aspirin or 18 mg/kg eugenol. For the
comparability of the experimental results, medium-dose
AEE, aspirin and eugenol were administered at the dose
of 0.11 mmol. In order to compare AEE with its precur-
sors, an equimolar combination of aspirin and eugenol
was designed in the experiment. Rats in CMC-Na group
were given 0.5 % CMC-Na at the dose of 30 mg/kg BW,
and the volume of CMC-Na was nearly equal in com-
parison with other drug suspensions. A detailed de-
scription of the study design is shown in Table 1. All
drugs and CMC-Na were administered intragastrically
for seven days, after which the rats were intraperito-
neally injected with 20 mg/kg k-carrageenan to induce
thrombosis.
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Carrageenan-induced rat tail thrombosis model
Carrageenan-induced rat tail thrombosis was induced as
described in the previous study [23].
Measurement of rat tail thrombosis length
After the last treatment with different drugs, each rat was
intraperitoneally injected with k-carrageenan. Swelling
and redness in rat tail were monitored. Thrombus lengths
were measured and photographed at 24 and 48 h.
Blood sampling
After the last measurement of thrombosis length at
48 h, rats were anesthetized with 10 % chloral hydrate
and blood samples were taken from the heart. According
to the requirement of the experiment, blood samples
were collected in different volume with different antico-
agulants. Serum for biochemical analysis and plasma for
ELISA were stored at −80 °C until the day of analysis.
All platelet aggregation and hemorheological tests were
performed within 3 h of blood collection.
Hemorheological tests
Blood samples of approximately 2 mL were collected
and anticoagulated with EDTA-K2, after which 0.8 mL
whole blood samples were prepared for whole blood vis-
cosity examination. The remaining blood samples were
centrifuged at 1000 g for 10 min to obtain plasma, after
which 0.5 mL of plasma was used for plasma viscosity
examination. A kone plate viscometer LBY-N6A analytical
instrument (Precil Company, Beijing, China) was used for
the measurement of whole blood viscosity and plasma vis-
cosity at 37.0 ± 0.5 °C. For whole blood viscosity, measure-
ments were made at three shear rates: 5, 100 and 200 s−1.
Plasma viscosity was measured at a shear rate of 100 s−1.
Assay of platelet aggregation
In vivo assessment of the anti-platelet aggregation effect
of AEE was performed using light transmission aggrego-
metry in platelet-rich plasma (PRP). About 2 mL blood
samples were collected and diluted by 3.8 % sodium cit-
rate on the proportion of 9:1 in vacuum tubes, which
were prepared for platelet aggregation analysis. Platelet
aggregation was assessed in PRP, which was obtained by
centrifugation of citrated whole blood at room temperature
for 10 min at 1000 rpm. Then, PRP was placed into two
cuvettes (0.25 mL PRP in each cuvette) and stirred with a
rotor at 37 °C for 5 min, after which 5 μM ADP and 5 mM
AA was added, respectively. The platelet-poor plasma
(PPP) was obtained by centrifugation of PRP at room
temperature for 10 min at 3000 rpm, which was used to
set zero. Aggregation was measured with a Chrono-log
Platelet Aggregometer Model 700 (Chrono-log Corp.,
USA). After the addition of an aggregating agent, light
transmission at maximal aggregation was recorded. The re-
sults are expressed as percentage of maximal aggregation.
Blood biochemical analysis
Blood samples of approximate 1 mL were collected into
vacuum tubes without anticoagulant, and centrifuged at
4000 rpm for 10 min to obtain serum. Serum was ana-
lyzed using an XL-640 automatic biochemistry analyzer
(Erba, German). Levels of total bilirubin (T-BIL), total
protein (TP), albumin (ALB), alanine transaminase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase
(ALP), gamma glutamyl transpeptidase (GGT), lactate de-
hydrogenase (LDH), blood urea nitrogen (BUN), creatin-
ine (CR), glucose (GLU), glutamic pyruvic transaminase
(GPT), creatine kinase (CK), calcium (Ca), phosphorus
(P), triglycerides (TG) and total cholesterol (TCH) were
analyzed in the experiment.
Measurement of plasma TXB2 and 6-keto-PGF1α
Samples anticoagulated with EDTA-K2 were centrifuged
at 1000 g for 10 min to obtain 200 μL of plasma for
TXB2 and 6-keto-PGF1α measurements. ELISA kit of
TXB2 was purchased from U.S.A TSZ Biological
Trade Co., Ltd. (New Jersey, USA) and 6-keto-PGF1α
ELISA kit was from Abcam Co., Ltd (Cambridge,
UK). The ELISA operation was followed the protocols
included with each kit.
Statistical analysis
Statistical analyses were carried out using SPSS (Statistical
Product and Service Solutions,IBM. Co., Armonk, NY,
USA). Data obtained from experiment was expressed as
mean ± standard deviation (SD). Statistical differences
were evaluated by ANOVA with least significant differ-
ence (LSD) test. P-values less than 0.05 were considered
to indicate statistical significance.





Control – – –
Model – – –
CMC-Na CMC-Na 30 –
Aspirin aspirin 20 0.11
Eugenol eugenol 18 0.11
AEE L AEE 18 0.06
AEE M AEE 36 0.11
AEE H AEE 72 0.22
Combination aspirin + eugenol 20 + 18 0.11
Ninety rats were divided into 9 groups (n = 10). CMC-Na was used as the
vehicle. The volumes of CMC-Na and drug suspension were nearly equal.
The molar quantity of medium-dose AEE, aspirin and eugenol are same at
0.11 mmol. An equimolar combination of aspirin and eugenol was used in
the study. Rats in the model, CMC-Na, aspirin, eugenol, AEE and combination
groups were intraperitoneally injected with 20 mg/kg k-carrageenan to
induce thrombosis
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Results
Effects on hemorheology
Hemorheological parameters were analyzed by routine
laboratory assays. The results are shown in Table 2. In
comparison with the control group, whole blood viscos-
ity and plasma viscosity were significantly increased in
model group (P < 0.01, or P < 0.05). There was no statis-
tical difference between CMC-Na and model groups. In
order to eliminate the influence of the vehicle, drug-
treated groups were compared with CMC-Na group.
Aspirin reduced whole blood viscosity at low shear
rate (P < 0.05), but did not influence whole blood viscosity
at medium and high shear rates. Whole blood viscosity at
low and medium shear rates in groups supplemented with
AEE were significantly lower than that of CMC-Na group
(P < 0.01). Whole blood viscosity at high shear rate was
also significantly reduced by low-dose AEE (P < 0.05). As-
pirin and eugenol remarkably reduced plasma viscosity
(aspirin: P < 0.01; eugenol: P < 0.05). Low and high doses
of AEE showed strong effects on reducing the plasma vis-
cosity values (P < 0.01). No change was observed on whole
blood viscosity and plasma viscosity between CMC-Na
and combination groups.
In order to find out the difference in results between
AEE and its precursors, multiple comparisons were car-
ried out. In the experiment, the molar quantities of as-
pirin, eugenol and medium-dose AEE were same. The
results are shown in Fig. 1. AEE showed stronger effects
on whole blood viscosity reduction at low shear rate
than eugenol and combination groups (P < 0.01, Fig. 1a).
In comparison with aspirin, eugenol and the combination
groups, AEE significantly reduced whole blood viscosity at
medium and high shear rates (P < 0.01 or P < 0.05 Fig. 1b
and c). Interestingly, the plasma viscosity values of each
AEE group was significantly lower than that of combin-
ation group (P < 0.01, Fig. 1d). Moreover, the mean
values of whole blood viscosity and plasma viscosity in
AEE groups were lower than other drug-treated groups.
Medium-dose AEE reduced whole blood viscosity more
effectively than eugenol (P < 0.01 or P < 0.05 Fig. 1a, b
and c). Moreover, medium-dose AEE showed better ef-
fects than aspirin on whole blood viscosity at medium
shear rate (P < 0.01 Fig. 1b). There were significant dif-
ferences on plasma viscosity and whole blood viscosity
(at low and medium shear rates) between AEE M and
combination groups (P < 0.01 Fig. 1a, b and d). To vary-
ing degrees, under the equimolar quantity of drugs,
medium-dose AEE stronger reduced whole blood vis-
cosity and plasma viscosity than aspirin, eugenol and
combination of them from the different hemorheological
parameters.
Effect of AEE on platelet aggregation in vivo
The results of platelet aggregation are shown in Table 3.
Platelet aggregation induced by AA and ADP was sig-
nificantly increased in model group (P < 0.01). No differ-
ence was observed between model and CMC-Na groups.
AEE, eugenol and aspirin remarkably reduced AA-
induced platelet aggregation than CMC-Na in varying
degrees (P < 0.05 or P < 0.01). The mean values in aspirin
and eugenol groups were 20.44 and 27.10, which indi-
cated aspirin had stronger effects than eugenol on inhi-
biting AA-induced platelet aggregation. In regard to
ADP-induced platelet aggregation, the values in aspirin,
combination, medium and high-dose AEE groups were
lower than CMC-Na group (P < 0.01).
The effects of different drug on platelet aggregation
were evaluated in the study (seen in Fig. 2). Medium- and
high-dose AEE showed stronger effects than aspirin on re-
ducing AA-induced platelet aggregation values (P < 0.01).
Meanwhile, three different doses of AEE displayed better
effects than eugenol (P < 0.01). ADP-induced platelet ag-
gregation values in low-dose AEE group were higher than
aspirin and combination groups (P < 0.01). Medium- and
Table 2 Drug effects on hemorheological parameters in k-carrageenan-induced rat tail thrombosis model (n = 10)
Groups WBV (mPa.s) PV (mPa.s)
Low shear rate (5 s−1) Medium shear rate (100 s−1) High shear rate (200 s−1)
Control 18.56 ± 3.03## 4.63 ± 0.77## 3.55 ± 0.79## 1.55 ± 0.28#
Model 27.75 ± 3.27 6.74 ± 0.78 5.24 ± 0.63 2.04 ± 0.47
CMC-Na 26.42 ± 2.66 6.87 ± 0.62 5.22 ± 0.52 1.97 ± 0.25
Aspirin 22.75 ± 3.57* 6.21 ± 0.62 5.21 ± 0.35 1.39 ± 0.13**
Eugenol 28.69 ± 2.93 6.87 ± 0.72 5.52 ± 0.79 1.63 ± 0.25*
AEE L 20.03 ± 2.75** 5.38 ± 0.78** 4.58 ± 0.67* 1.32 ± 0.12**
AEE M 22.60 ± 2.28** 5.48 ± 0.86** 4.74 ± 0.52 1.68 ± 0.61
AEE H 22.25 ± 3.60** 5.14 ± 0.69** 4.63 ± 0.62 1.50 ± 0.14**
Combination 27.45 ± 2.90 6.58 ± 1.06 5.28 ± 0.63 2.19 ± 0.30
After the last measurement of rat tail thrombosis length at 48 h, 0.8 mL of whole blood and 0.5 mL of plasma were collected for hemorheological parameter tests.
Data are expressed as mean ± SD. #P < 0.05, ##P < 0.01 compared with model group. *P < 0.05, **P < 0.01 compared with CMC-Na group. WBV whole blood viscosity,
PV plasma viscosity. AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and eugenol (molar ratio 1:1)
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high-dose AEE significantly inhibited ADP-induced plate-
let aggregation more effectively than eugenol (P < 0.01).
The values of ADP-induced platelet aggregation in high-
dose AEE group were lower than that in combination
group (P < 0.05). Based on these results, under the same
molar quantity, medium-dose AEE showed better effects
than aspirin and eugenol on AA-induced platelet aggrega-
tion and possessed more effective effects of inhibiting
ADP-induced platelet aggregation than eugenol.
Blood biochemical results
The results of blood biochemistry are given in Table 4.
In comparison with control group, TP, ALB, ALP,
ALT, Ca and TG in model group were significantly
reduced (P < 0.01), AST and TCH were remarkably
elevated (P < 0.05 and P < 0.01). The results of ALB, ALT
and LDH between model and CMC-Na groups showed
some differences (P < 0.05, or P < 0.01). When compared
with CMC-Na group, aspirin significantly reduced the
levels of T-BIL, AST, LDH, TG and TCH, and elevated the
levels of TP, ALB, BUN and Ca (P < 0.05, or P < 0.01). In
addition, there was no significant difference between
CMC-Na and eugenol groups.
In comparison with CMC-Na group, the levels of
ALB and Ca were significantly increased in AEE groups
(P < 0.05, or P < 0.01), whereas TCH was significantly re-
duced (P < 0.05, or P < 0.01). Low- and medium-dose AEE
significantly increased the level of TP and reduced the
level of T-BIL (P < 0.01). The TG and BUN levels in high-
dose AEE group were significantly reduced (P < 0.05). In
Fig. 1 Comparative effects of aspirin, eugenol and AEE on hemorheological parameters (n = 10). (a-c): whole blood viscosity at the shear rates of 5 s-1,
100 s-1 and 200 s-1. (d): plasma viscosity at the shear rate of 100 s-1. #P < 0.05, ##P < 0.01 compared with model group. aP < 0.05, aaP < 0.01 compared
with aspirin group. bP < 0.05, bbP < 0.01 compared with eugenol group. cP < 0.05, ccP < 0.01 compared with combination group. Under the same molar
quantity, medium dose of AEE showed better effects than its precursors on whole blood viscosity and plasma viscosity reduction in varying degrees.
AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg. Combination: combination of aspirin and eugenol (molar ratio 1:1)
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comparison with the CMC-Na group, the levels of ALB,
AST, LDH and BUN in combination group were signifi-
cantly elevated (P < 0.01). The differences in blood bio-
chemical indexes among the groups treated with three
doses of AEE were dose-independent.
Effects of AEE on TXB2 and 6-keto-PGF1α
The results of TXB2 and 6-keto-PGF1a are shown in
Table 5. TXB2 and TXB2/6-keto-PGF1α ratio were ele-
vated in model group in comparison with those in con-
trol group, but 6-keto-PGF1α was declined (P < 0.01).
There was no difference in TXB2 between CMC-Na and
model groups. However, a significant decrease of 6-keto-
PGF1α and an increase of TXB2/6-keto-PGF1α ratio were
observed (P < 0.01). Eugenol and aspirin significantly in-
creased 6-keto-PGF1α and lowered TXB2/6-keto-PGF1α
ratio than CMC-Na (P < 0.01). In comparison with
CMC-Na group, low-, medium- and high-dose AEE had
significantly increased 6-keto-PGF1α and reduced TXB2
with a drop of TXB2/6-keto-PGF1α ratio (P < 0.01). No
dose response relationship was observed in AEE groups
on TXB2 and 6-keto-PGF1α.
Figure 3 shows the effects different drugs on TXB2
and 6-keto-PGF1α. In comparison with aspirin and eu-
genol, AEE reduced TXB2 and 6-keto-PGF1α to varying
degrees with the exception of 6-keto-PGF1α in medium-
dose AEE group. TXB2 in high-dose AEE group were
higher than combination group (P < 0.05). Three differ-
ent doses of AEE remarkably lowered 6-keto-PGF1α in
comparison with combination group (P < 0.05 or P <
0.01). Under the same molar quantity, medium-dose
AEE significantly reduced TXB2 than aspirin and eu-
genol (P < 0.05 or P < 0.01). Results of 6-keto-PGF1α in
medium-dose AEE group were higher than eugenol and
combination groups. Meanwhile, the TXB2/6-keto-
PGF1α ratio in medium-dose AEE group was signifi-
cantly lower than that in eugenol (P < 0.01). Therefore,
equimolar AEE possessed better effects on reducing
TXB2, increasing 6-keto-PGF1α and regulation of TXB2/
6-keto-PGF1α ratio than its precursors.
Discussion
Several chemical drugs are used to prevent or treat
thrombosis such as clopidogrel, ticlopidine, dabigatran
and apixaban. However, available antithrombosis agents
still have some limitations such as gastrointestinal dam-
age and hemorrhage. Therefore, there is an obvious
need for more efficacious and alternative treatment op-
tions for thrombosis. A previous study showed that
AEE could reduce platelet aggregation in vitro, fibrino-
gen concentration and regulate coagulation parameters,
indicating that AEE was a promising drug candidate for
Table 3 Effect of AEE on platelet aggregation in k-carrageenan-
induced rat tail thrombosis model (n = 10)
Groups AA-induced PAg ADP-induced PAg
Control 8.70 ± 1.34## 31.90 ± 2.77##
Model 29.00 ± 1.49 50.10 ± 3.34
CMC-Na 30.10 ± 2.13 51.90 ± 2.28
Aspirin 20.44 ± 2.74** 40.89 ± 4.26**
Eugenol 27.10 ± 3.14* 50.10 ± 2.23
AEE L 18.70 ± 3.49** 49.30 ± 2.79
AEE M 11.80 ± 3.70** 43.30 ± 3.13**
AEE H 15.70 ± 3.43** 42.20 ± 3.26**
Combination 11.50 ± 2.50** 45.50 ± 3.17**
5 μM ADP and 5 mM AA were added separately to platelet-rich plasma (PRP),
which was used to assess platelet aggregation. Results are expressed as the
percentage of maximal aggregation. Data are expressed as mean ± SD. #P < 0.05,
##P < 0.01 compared with the model group. *P < 0.05, **P < 0.01 compared with
the CMC-Na group. PAg: platelet aggregation. AEE L: AEE 18 mg/kg; AEE M:
36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and
eugenol (molar ratio 1:1)
Fig. 2 Comparative effects of aspirin, eugenol and AEE on platelet aggregation in k-carrageenan-induced rat tail thrombosis model (n = 10).
#P < 0.05, ##P < 0.01 compared with model group. aP < 0.05, aaP < 0.01 compared with aspirin group. bP < 0.05, bbP < 0.01 compared with eugenol
group. cP < 0.05, ccP < 0.01 compared with combination group. No difference was observed between model and CMC-Na groups, which indicated
that CMC-Na made no influence on PAg index. AEE showed strong effects than aspirin and eugenol at the same molar quantity. PAg:platelet
aggregation. AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and eugenol (molar ratio 1:1)
Ma et al. BMC Veterinary Research  (2016) 12:108 Page 6 of 10
preventing cardiovascular diseases [23]. It was import-
ant to characterize its possible mechanism from differ-
ent views.
Blood hemorheology is an integrated branch of physics
and medicine. Increased blood viscosity is a risk factor
for thrombosis, atherosclerosis and other cardiovascular
events [24]. The increased blood and plasma viscosity in
model group can be related to the acute inflammation
caused by k-carrageenan injection [23, 25]. AEE de-
creased whole blood and plasma viscosity, which con-
tributed to ameliorating blood circulation. It also proved
that AEE could reduce fibrinogen concentration and
normalize blood components [23]. Changes of blood
components, especially the reduction of hematocrit, may
be responsible for the decrease of viscosity. Additionally,
blood viscosity is also determined by shear rate, red
blood cell deformability and aggregation. The effects of
AEE and its dosage influence on hemorheological pa-
rameters should be assessed in the future studies. Some
differences were observed between aspirin and combin-
ation groups in hemorheological parameters. The mean
values of plasma component such as TP, ALB, TG and
TCH in aspirin group were lower than those in combin-
ation group, which may be the reason for the decrease
in plasma viscosity. It was speculated that the differences
in RBC deformability and aggregation in aspirin and
combination groups were responsible for the different
results in whole blood viscosity.
Salicylic acid is the major metabolite of AEE confirmed
by in vivo and in vitro experiments [26]. As a classic drug,
aspirin is used therapeutically in the prevention of cardio-
vascular disease by blocking TXA2 synthesis. Salicylic acid,
also the main metabolite of aspirin, is the primary sub-
stance responsible for pharmacological function of aspirin
on platelet aggregation. AEE and aspirin share the same
metabolite as salicylic acid; therefore, AEE and aspirin
likely inhibit platelet aggregation via similar mechanism.
The effects of eugenol on human platelet aggregation
had been investigated and proved that eugenol was a
strong platelet aggregation inhibitor [12, 13]. Vascular
endothelial cell damage caused by k-carrageenan may
be the reason for the increased platelet aggregation in
Table 4 Biochemical parameters in rats intragastrically administered different drugs (n = 10)
Variables Unit Control Model CMC-Na Aspirin Eugenol AEE L AEE M AEE H Combination
T-BIL umol/L 0.90 ± 0.13 0.97 ± 0.19 1.00 ± 0.17 0.74 ± 0.12** 1.11 ± 0.17 0.72 ± 0.15** 0.65 ± 0.10** 0.86 ± 0.12 1.17 ± 0.17*
TP g/L 58 ± 2.9## 53 ± 4.3 50 ± 3.4 60 ± 2.2** 50 ± 4.7 59 ± 2.4** 60 ± 3.3** 58 ± 4.1** 61 ± 3.9**
ALB g/L 23 ± 1.0## 20 ± 1.4 18 ± 1.1## 20 ± 0.8* 19 ± 1.4 21 ± 2.3** 21 ± 0.7** 20 ± 1.1* 22 ± 1.2**
ALT U/L 69 ± 10## 57 ± 9 67 ± 12# 61 ± 5 68 ± 13 65 ± 6 65 ± 6 58 ± 14 67 ± 13
AST U/L 79 ± 11# 93 ± 10 85 ± 12 65 ± 8** 96 ± 14 76 ± 10 75 ± 16 74 ± 12 120 ± 14**
ALP U/L 240 ± 19## 145 ± 22 156 ± 22 178 ± 27 137 ± 23 180 ± 25 181 ± 21 177 ± 11 172 ± 54
GGT U/L 3.16 ± 0.49 3.34 ± 0.44 3.20 ± 0.25 3.44 ± 0.45 3.15 ± 0.67 3.55 ± 0.57 3.72 ± 0.64 3.61 ± 0.51 3.62 ± 0.60
LDH U/L 141 ± 28 129 ± 29 161 ± 18# 123 ± 31* 190 ± 27 128 ± 20 126 ± 22 140 ± 38 227 ± 36**
BUN mmol/L 8.0 ± 0.6 8.9 ± 1.7 9.9 ± 1.7 11.5 ± 1.4* 10.3 ± 1.9 9.4 ± 0.7 9.7 ± 1.5 8.3 ± 0.9 * 12.5 ± 1.3**
CR umol/L 27.3 ± 4.6 29.3 ± 4.9 29.0 ± 4.8 37.4 ± 3.6* 31.6 ± 4.1 24.9 ± 3.8 32.1 ± 4.6 26.2 ± 3.2 36.4 ± 4.7**
Glu mmol/L 8.01 ± 0.68 8.11 ± 0.68 7.98 ± 0.53 7.78 ± 0.38 7.52 ± 0.30 7.50 ± 0.81 7.40 ± 0.25 7.57 ± 0.62 7.90 ± 0.81
Ca mmol/L 2.42 ± 0.06## 2.08 ± 0.10 2.12 ± 0.15 2.30 ± 0.05** 2.12 ± 0.12 2.47 ± 0.12** 2.35 ± 0.05** 2.24 ± 0.14* 2.19 ± 0.06
P mmol/L 3.31 ± 0.19 3.47 ± 0.25 3.50 ± 0.60 3.36 ± 0.40 3.64 ± 0.43 3.23 ± 0.45 3.36 ± 0.20 3.54 ± 0.15 3.53 ± 0.22
TG mmol/L 1.19 ± 0.21## 0.66 ± 0.09 0.78 ± 0.06 0.56 ± 0.09* 0.69 ± 0.16 0.71 ± 0.19 0.59 ± 0.15 0.58 ± 0.27* 0.77 ± 0.21
TCH mmol/L 1.37 ± 0.07## 1.98 ± 0.08 1.81 ± 0.23 1.53 ± 0.17** 1.93 ± 0.18 1.62 ± 0.12* 1.56 ± 0.18* 1.55 ± 0.26** 1.96 ± 0.29
After the last measurement of thrombosis length at 48 h, blood was drawn from the heart. Serum samples were prepared by centrifugation and analyzed using
an automatic biochemistry analyzer. #P < 0.05, ##P < 0.01 compared with the model group. *P < 0.05, **P < 0.01 compared with the CMC-Na group. AEE L: AEE
18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and eugenol (molar ratio 1:1)
Table 5 Effects of each treatment on TXB2, 6-keto-PGF1α and
the TXB2/6-keto-PGF1a ratio in k-carrageenan-induced rat tail
thrombosis model (n = 10)
Groups TXB2 6-keto-PGFlα TXB2/6-keto-PGFlα
Control 498 ± 32## 889 ± 28## 0.56 ± 0.04##
Model 696 ± 39 586 ± 24 1.19 ± 0.08
CMC-Na 703 ± 37 550 ± 22## 1.28 ± 0.08##
Aspirin 658 ± 44* 741 ± 23** 0.89 ± 0.06**
Eugenol 678 ± 58 699 ± 30** 0.97 ± 0.09**
AEE L 605 ± 22** 667 ± 17** 0.91 ± 0.04**
AEE M 612 ± 45** 737 ± 13** 0.83 ± 0.07**
AEE H 644 ± 23** 599 ± 26** 1.08 ± 0.07**
Combination 598 ± 51** 701 ± 31** 0.86 ± 0.10**
Blood samples anticoagulated with EDTA-K2 were centrifuged at 1000 g for
10 min to obtain plasma, which was analyzed using ELISA kits. Data are
expressed as mean ± SD. ##P < 0.01 compared with the model group. *P < 0.05,
**P < 0.01 compared with the CMC-Na group. AEE L: AEE 18 mg/kg; AEE M:
36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination of aspirin and
eugenol (molar ratio 1:1)
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model group [18]. The vehicle, CMC-Na, had no effect
on platelet aggregation. In the case of equal molar
quantity, AEE inhibited the platelet aggregation and
showed stronger effects than eugenol on AA and ADP-
induced platelet aggregation, and better effects than as-
pirin on AA-induced platelet aggregation. Based on the
results, the effect of AEE on platelet aggregation is
likely produced by both salicylic acid and eugenol. AEE
is decomposed into salicylic acid and eugenol by the
enzyme after absorption, after which salicylic acid and
eugenol as the major metabolites showed their original
activities and acted synergistically to increase the inhibi-
tory effect on platelet aggregation. Previous studies have
confirmed that platelet aggregation is an important influ-
ence in blood viscosity [27]. Thus, the reduced platelet ag-
gregation caused by AEE was another factor contributing
to the decreases of blood and plasma viscosity.
In order to explore the further mechanisms of inhibit-
ing platelet aggregation, the levels of TXB2 and 6-keto-
PGF1α in plasma were measured. TXB2 and 6-keto-
PGF1α are the stable hydrolysis products of thromboxane
A2 (TXA2) and prostacyclin I2 (PGI2), respectively.
TXA2 is a potent inducer of platelet aggregation and
vasoconstriction [6]. PGI2 is a powerful vasodilator that
inhibits platelet aggregation [28]. Arachidonate is a pre-
cursor of both PGI2 and TXA2. Cyclooxygenase (COX)
plays an important role in arachidonate metabolic path-
ways to generate PGI2 and TXA2 [29]. Some evidences
have demonstrated that both aspirin and eugenol inhibit
COX activity [30–32]. Aspirin, as an inhibitor of COX,
could reduce both the level of TXB2 and 6-keto-PGF1α.
However, the level of 6-keto-PGF1α in aspirin group was
higher than that of CMC-Na group. The previous study
showed that aspirin significantly decreased the length of
rat tail thrombosis [23]. Thrombosis formation may pro-
duce the reductive effects on 6-keto-PGF1α. Aspirin in-
hibits the thrombosis formation in the rat tail, and then
weakens the decreasing effects caused by k-carrageenan
on 6-keto-PGF1α. Suppression of inflammation by aspirin
may be the reason of reducing rat tail thrombosis length
[33]. Platelets primarily process PGH2 to TXA2 and vascu-
lar endothelial cells primarily process PGH2 to PGI2. As-
pirin selectively inhibits the production of TXA2 in
platelet, while sparing endothelial PGI2 synthesis [34].
New cyclooxygenase could be produced in endothelial
cells, but cannot in anucleate platelets. It was speculated
that the different effects of aspirin on platelets and endo-
thelial cells and the newly produced cyclooxygenase from
endothelial cells may be the reasons for the raised 6-keto-
PGF1α in aspirin group. Under equal molar quantity, AEE
produced better effects than single using of eugenol
or aspirin on TXB2 and 6-keto-PGF1α. According to
these results, AEE might significantly down-regulate
TXB2 and up-regulate 6-keto-PGF1α with the TXB2/6-
keto-PGF1α decreased, indicating that the antithrombotic
action of AEE was associated with the regulation of TXB2
and 6-keto-PGF1α.
Analysis of blood biochemical parameters could help
veterinarians and breeders assess the general health status
of animals [35, 36]. Injection of k-carrageenan disturbed
the blood biochemical profile through the increase of AST
and TCH and the reduction of TP, ALB, ALP, ALT, Ca
and TG in model group. These alterations may be related
to the stress caused by acute inflammation. Previous study
showed that leukocyte and monocyte counts were signifi-
cantly increased after k-carrageenan injection, which indi-
cated that the rats suffered from acute and systemic
inflammation [23]. Intense inflammation could cause the
disorder of liver function, and then result in the changes
of biochemical profile [37, 38]. In the present study, the
reduction of TP, ALB, ALP and the increasing of AST in
model group indicated abnormal liver function. Ca, a key
factor in thrombosis formation, may be depleted in
thrombosis formation process, which may be the reason
for the reduction of Ca in model group. The increase of
TCH and the reduction of TG may be related to rat body
Fig. 3 Comparative effects of aspirin, eugenol and AEE on TXB2, 6-keto-PGF1α and TXB2/6-keto-PGF1a ratio in different groups (n = 10).
#P < 0.05,
##P < 0.01 compared with model group. aP < 0.05, aaP < 0.01 compared with aspirin group. bP < 0.05, bbP < 0.01 compared with eugenol group.
cP < 0.05, ccP < 0.01 compared with combination group. AEE L: AEE 18 mg/kg; AEE M: 36 mg/kg; AEE H: AEE 72 mg/kg; Combination: combination
of aspirin and eugenol (molar ratio 1:1)
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response [39]. It has been proved that AEE could regulate
blood lipids in hyperlipidemic rats [40]. The results of TG
and TCH indexes in this experiment were similar as found
in previous studies [16, 40]. AEE showed positive effects
on changing biochemical characters and possessed the
ability to normalize the biochemical profile following in-
flammation, which may be supported by the prolonged
time of drug action [41]. In the present study, the blood
biochemical results in eugenol group showed no differ-
ences in comparison with CMC-Na group. Several reasons
may be for these results. Blood biochemical parameters
were drastically changed by k-carrageenan injection,
which may mask the changes caused by eugenol. More-
over, the dosage of eugenol used in the experiment or eu-
genol itself was unable to affect biochemical parameters.
Previous studies indicated that administration of 150 mg
eugenol for 7 days had no significant effects on clinical
biochemical parameters in humans [42].
CMC-Na is a reliable drug carrier that is used in a
wide range of applications in the pharmaceutical indus-
try [43, 44]. In this study, CMC-Na as vehicle had influ-
ence on 6-keto-PGFlα, TXB2/6-keto-PGF1a ratio, ALB,
ALT and LDH. In order to demonstrate the activity of
AEE, the comparisons were carried out between CMC-
Na and treated groups. Therefore, the effect of CMC-Na
was eliminated. Tween 80 is widely applied in emulsifying
and dispersing substances in medicinal products. In the
present study, Tween 80 was used to prepare eugenol. It
had been confirmed that the body had a great tolerance to
Tween 80 [45]. The effects of Tween 80 and combination
of CMC-Na and Tween 80 were not investigated in
this experiment.
AEE on the design of prodrug principle contains ester
bond structure that is decomposed easily. Pharmacokinet-
ics studies showed that the plasma concentration of AEE
itself was extremely low; indeed it was not detectable in
plasma. Therefore, it is speculated that the degradation
products of AEE such as salicylic acid and eugenol are re-
sponsible for its effects. Salicylic acid and eugenol may play
an efficient role and interact in a synergistic manner to
prevent thrombosis formation. More studies should be
conducted to investigate the action mechanism of AEE on
thrombosis prevention. In addition, as a promising chem-
ical compound, AEE should be studied in preclinical exper-
iments to assess its therapeutic effects in various species.
Conclusion
The results obtained in our study showed that AEE had
potent antithrombotic effects in rats with k-carrageenan-
induced tail thrombosis. Moreover, AEE showed better
antithrombotic effect than its precursors under same molar
quantity. From the findings, the preventive effect of AEE
may come from antiplatelet aggregation, reducing blood
and plasma viscosity, balancing TXB2/6-keto-PGF1a ratio
and normalizing blood biochemical parameters. These
therapeutic effects of AEE may be related to the
synergetic actions of aspirin and eugenol. It may be
concluded that AEE was a good candidate for anti-
thrombotic agent. These findings provide new insight
into the action mechanism of AEE on preventing
thrombosis. More studies are necessary to investigate
its mechanism of action such as the protective effects
of vascular endothelial cells, the way on anti-platelet
aggregation and the influences on metabolic profile.
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